# PT-141 for Women in the Research Literature | Bremelanotide & HSDD

> PT-141 for women: the FDA-approved bremelanotide indication (premenopausal HSDD), the RECONNECT Phase 3 endpoints, and the brain-imaging evidence — cited and approval-aware.

The one place PT-141 carries an FDA approval: premenopausal hypoactive sexual desire disorder. The trials, the endpoints, and the open debate, read carefully.

## Start here

PT-141 for women is the only use of this peptide that the FDA has actually approved — and even there the door is narrow. The approval, granted in 2019, covers premenopausal women with hypoactive sexual desire disorder (HSDD): a persistent, distressing lack of sexual desire that is not better explained by another condition [3][7]. Postmenopausal women are outside the approval.

What makes the female evidence the strongest in the whole PT-141 story is that it rests on two large, identical, placebo-controlled trials and a year-long follow-up, not on extrapolation [3][4]. The benefit those trials measured was statistically clear but modest in size, and independent reviewers continue to debate how meaningful it is in daily life [11]. Nausea was the common cost [4]. Below, the trials, the brain-imaging mechanism, and the honest controversy — each tied to its source.

## The pivotal trials: RECONNECT

The approval rests on RECONNECT — two identical Phase 3 randomized controlled trials enrolling 1,267 premenopausal women with HSDD [3]. Bremelanotide 1.75 mg, injected subcutaneously on an as-needed basis, met both coprimary endpoints in both studies over 24 weeks: sexual desire rose on the Female Sexual Function Index desire score by an integrated +0.35 (P<.001), and desire-related distress fell on a validated distress-scale item by −0.33 (P<.001) [3].

The durability data came from a 52-week open-label extension in which 684 women continued treatment. Desire improvements were sustained, and no new safety signals emerged [4]. The most common drug-related effects in that long-term window were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. A 2026 meta-analysis pooling the trial evidence reported improvements in total Female Sexual Function Index scores and in the desire and arousal subscales [12].

## How it works in the female brain

The female evidence is unusual in that the mechanism has been imaged directly. In a randomized, double-blind, placebo-controlled crossover study, 31 premenopausal women with HSDD underwent functional MRI after MC4R agonism [5]. Activating the receptor significantly increased sexual desire for up to 24 hours and altered how the brain processed erotic stimuli — enhancing connectivity between the amygdala and insula and changing activity in cerebellar and supplementary-motor regions [5].

That is mechanistic confirmation that this is a brain effect, not a blood-flow effect [5]. The preclinical groundwork pointed the same way: in female rats, the peptide selectively increased appetitive, solicitational sexual behaviors — the desire-driven kind — without changing reflexive behaviors or general movement, the first time a drug was shown to act on appetitive female sexual behavior [2]. Reviews of the neurobiology of the female sexual response place melanocortins among the key excitatory signals of desire and discuss bremelanotide as a centrally acting agent on that pathway [10].

## The honest controversy

A careful reading of PT-141 for women has to include the criticism. Independent re-analyses argue that while the effects on desire and distress are statistically significant, they are small, and they question whether the chosen outcome measures capture a clinically meaningful change [11]. One critique notes that, on average, bremelanotide produced no additional enjoyable sexual experiences in the trials, and argues the approval leaned on the precedent of an earlier desire drug [11].

There is also a broader debate the literature itself flags: a lack of consensus on how HSDD should be diagnosed, and an ongoing ethical argument about the medicalization of low desire [8]. None of this erases the approval or the positive endpoints — but a regulatory-careful digest reports the modest effect size and the live debate next to the wins, not after them.

---

A regulatory-careful reading room on PT-141 (bremelanotide): the single 2019 approval for premenopausal HSDD held distinct from every off-label and research-chemical use, each figure logged to the trials or the FDA label — a reading desk organized around the prescription record, never a place that writes, fills, or fulfils one.